The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Open accessAbstract
Over the last few decades, study of cancer in mouse models has gained popularity. Sophisticated genetic manipulation technologies and commercialization of these murine systems have made it possible to generate mice to study human disease. Given the large socio-economic burden of cancer, both on academic research and the health care industry, there is a need for in vivo animal cancer models that can provide a rationale that is translatable to the clinic. Such a bench-to-bedside transition will facilitate a long term robust strategy that is economically feasible and clinically effective to manage cancer. The major hurdles in considering mouse models as a translational platform are the lack of tumor heterogeneity and genetic diversity, which are a hallmark of human cancers. The present review, while critical of these pitfalls, discusses two newly emerging concepts of personalized mouse models called “Mouse Avatars” and Co-clinical Trials. Development of “Mouse Avatars” entails implantation of patient tumor samples in mice for subsequent use in drug efficacy studies. These avatars allow for each patient to have their own tumor growing in an in vivo system, thereby allowing the identification of a personalized therapeutic regimen, eliminating the cost and toxicity associated with non-targeted chemotherapeutic measures. In Co-clinical Trials, genetically engineered mouse models (GEMMs) are used to guide therapy in an ongoing human patient trial. Murine and patient trials are conducted concurrently, and information obtained from the murine system is applied towards future clinical management of the patient’s tumor. The concurrent trials allow for a real-time integration of the murine and human tumor data. In combination with several molecular profiling techniques, the “Mouse Avatar” and Co-clinical Trial concepts have the potential to revolutionize the drug development and health care process. The present review outlines the current status, challenges and the future potential of these two new in vivo approaches in the field of personalized oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Phenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Characterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · cited 2×
“Identification of Her2 amplification as a genetic lesion in cetuximab-resistant colorectal tumors [52]”
BackgroundReconstruction of functionally normal and malignant human breast tissues in mice
Kuperwasser, C., Chavarria, T., Wu, M., Magrane, G., Gray, J. W., Carey, L., Richardson, A., & Weinberg, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401064101 · Cited by 804
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
He, L.-Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/ng0298-126 · Cited by 557
Cited by
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Systems Biology of Cancer Metastasis
Suhail, Y., Cain, M. P., Vanaja, K., Kurywchak, P. A., Levchenko, A., Kalluri, R., & Kshitiz (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.003 · Cited by 452
Preclinical mouse solid tumour models: status quo, challenges and perspectives
Gengenbacher, N., Singhal, M., & Augustin, H. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.92 · Cited by 332
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Saleh, M., Asadzadeh Aghdaei, H., & Baghaei, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03405-8 · Cited by 326
The Generation and Application of Patient-Derived Xenograft Model for Cancer Research
Jung, J., Seol, H. S., & Chang, S. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.307 · Cited by 310
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Block, K. I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A. R. M. R., Amin, A., Aquilano, K., Arbiser, J., Arreola, A., Arzumanyan, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.007 · Cited by 300
Barbosa, M. A. G., Xavier, C. P. R., Pereira, R. F., Petrikaitė, V., & Vasconcelos, M. H. (2021) · Cancers · doi:10.3390/cancers14010190 · Cited by 285
“Nevertheless, regarding the PDTX approach, the engraftment process, plus the maintenance of the PDTX and the molecular profiling required to evaluate if the tumor isolated from the mouse mimics the original patient tumor, are very expensive [21].”
BackgroundCould 3D models of cancer enhance drug screening?
Brancato, V., Oliveira, J. M., Correlo, V. M., Reis, R. L., & Kundu, S. C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119744 · Cited by 281
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
Zhang, T., Li, J., Yin, F., Lin, B., Wang, Z., Xu, J., Wang, H., Zuo, D., Wang, G., Hua, Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.270 · Cited by 132
Impact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125
Automated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs
Janssens, D. H., Wu, S. J., Sarthy, J. F., Meers, M. P., Myers, C. H., Olson, J. M., Ahmad, K., & Henikoff, S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0243-8 · Cited by 73
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 83
“However, these models are expensive to establish and maintain, and they raise questions regarding tumor stage at engraftment—whether during early growth or after multiple mutations and metastatic progression—which directly influences therapeutic outcomes [180].”
A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture
Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-0799 · Cited by 61
“Defining features of this 405 microfluidic system are: (1) relatively large (tumor) tissue slices can be loaded, (2) flow of culture media 406 both above and under the tissue slice to sustain constant delivery of nutrients and gasses and removal of 407 waste products, (3) mainly silicon-based components, (4) standard…”
BackgroundDong, R., Qiang, W., Guo, H., Xu, X., Kim, J. J., Mazar, A., Kong, B., & Wei, J.-J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0318-6 · Cited by 49
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
Metadata
- Authors
- Malaney, P., Nicosia, S. V., & Davé, V.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 344
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2102624911
- Cited by
- 289
- References
- 93
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.